LSE · GDR.L
Genedrive Plc
£0.01£0.00 (0.0%)
Genedrive Plc’s quoted price sits in the lower half of its reported 52-week range, 37.1% below the high.
Loading market information…
LSE · THAT.L · GBp
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 08:04 AM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
Thalia Therapeutics Plc’s quoted price sits in the lower half of its reported 52-week range, 39.47% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Thalia Therapeutics Plc’s forward annual dividend is £0.36 per share, paid semi-annual. The forward yield is 6,260.87% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Thalia Therapeutics Plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Thalia Therapeutics Plc, a specialized pharmaceutical company established in 1979 and headquartered in Chellaston, UK, focuses on developing advanced nanoparticle silica delivery systems. These innovative systems are designed to enhance the cellular uptake and effectiveness of various cancer treatments and vaccines. The company's product portfolio includes Nuvec, a unique silica nanoparticle delivery platform distinguished by its irregular surface structure that effectively encapsulates and safeguards genetic material such as siRNA, RNA, and DNA. Additionally, it offers Liptide, a specialized platform engineered for the targeted delivery of a proprietary siRNA sequence to silence fibrotic genes. Thalia Therapeutics is also advancing N4 101, an orally administered inflammation inhibitor currently undergoing pre-clinical evaluation for the treatment of inflammatory bowel disease, alongside ECP105, which is being developed to prevent ocular scarring. The firm, previously known as N4 Pharma Plc, officially rebranded to Thalia Therapeutics Plc in March 2026.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:40 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£0.01£0.00 (0.0%)
Genedrive Plc’s quoted price sits in the lower half of its reported 52-week range, 37.1% below the high.
£0.07£0.00 (0.0%)
Tissue Regenix Group plc’s quoted price sits in the lower half of its reported 52-week range, 89.02% below the high.
£0.01-£0.00 (-0.34%)
Proteome Sciences plc’s quoted price sits in the lower half of its reported 52-week range, 66.93% below the high.
£0.09-£0.00 (-2.78%)
MyHealthChecked PLC’s quoted price sits in the lower half of its reported 52-week range, 58.33% below the high.
£0.00£0.00 (0.0%)
Surgical Innovations Group plc’s quoted price sits in the lower half of its reported 52-week range, 33.33% below the high.
£0.00-£0.00 (-2.86%)
Theracryf Plc’s quoted price sits in the lower half of its reported 52-week range, 36.57% below the high.
£0.09£0.00 (0.0%)
CRISM Therapeutics Corporation’s quoted price sits in the lower half of its reported 52-week range, 52.7% below the high.
£0.00+£0.00 (+1.9%)
Oxford BioDynamics Plc’s quoted price sits in the lower half of its reported 52-week range, 68.38% below the high.
